immunotherapies fully funded for the coming year.
"financial break even in the last quarter of calendar year 2018 with the expectation of being profitable for the full calendar year 2019."
Given that losses should decrease, they may have enough money to see them through. Cutting it fine though.
Ann: FY17 Full Year Results Announcement, page-2
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.70 |
Change
-0.300(1.58%) |
Mkt cap ! $359.4M | |||
| Open | High | Low | Value | Volume |
| $19.00 | $19.00 | $18.62 | $180.3K | 9.596K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 475 | $18.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.91 | 100 | 1 |
View Market Depth
| Last trade - 14.41pm 20/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |